Literature DB >> 9554350

Health outcomes variables important to patients in the treatment of erectile dysfunction.

C Hanson-Divers1, S E Jackson, T F Lue, S Y Crawford, R C Rosen.   

Abstract

PURPOSE: Erectile dysfunction is underreported and the rate of noncompliance with therapy is high. The National Institutes of Health Consensus Conference on Impotence endorsed the need for outcomes research of the various approaches to treatment. The purpose of our exploratory study was to begin that process through identification of erectile dysfunction treatment outcomes variables that are important to men.
MATERIALS AND METHODS: The study format consisted of focus group meetings. The goal of the discussions was to identify variables that are important to men when choosing among and judging the success of treatment modalities for erectile dysfunction. After discussion participants were individually asked to identify the 10 variables that they considered important and rank the 5 most important variables. An importance score reflecting group consensus was calculated for each variable.
RESULTS: Success and negative outcomes were identified as the 2 most important outcomes variables for all treatment modalities. Participants defined success in several ways. The most important measures of success were cure, pleasure and partner satisfaction. Negative outcome was defined as negative consequences associated with treatment.
CONCLUSIONS: The focus group discussion assisted in identifying and defining outcomes variables important to patients with erectile dysfunction. We believe that understanding issues and outcomes important to such patients is necessary to increase compliance with treatment and, thereby, increase the success of treatment of this widespread condition.

Entities:  

Mesh:

Year:  1998        PMID: 9554350     DOI: 10.1097/00005392-199805000-00037

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  17 in total

1.  Treatment expectations of men with ED and their female partners: an exploratory qualitative study based on grounded theory.

Authors:  S Henninger; C Höhn; C Leiber; M M Berner
Journal:  Int J Impot Res       Date:  2015-06-11       Impact factor: 2.896

2.  The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions.

Authors:  Edward C F Wilson; Emma S McKeen; Paul A Scuffham; Martin C J Brown; Kevan Wylie; Geoff Hackett
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 3.  Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough?

Authors:  Mikkel Fode; Georgios Hatzichristodoulou; Ege Can Serefoglu; Paolo Verze; Maarten Albersen
Journal:  Nat Rev Urol       Date:  2017-07-25       Impact factor: 14.432

Review 4.  [How effective are PDE-5 inhibitors?].

Authors:  K-P Jünemann
Journal:  Urologe A       Date:  2003-03-25       Impact factor: 0.639

5.  Udenafil: efficacy and tolerability in the management of erectile dysfunction.

Authors:  Sung Gu Kang; Je Jong Kim
Journal:  Ther Adv Urol       Date:  2013-04

Review 6.  A review of the efficacy and safety of mirodenafil in the management of erectile dysfunction.

Authors:  Min Chul Cho; Jae-Seung Paick
Journal:  Ther Adv Urol       Date:  2016-01-19

Review 7.  Restorative Therapies for Erectile Dysfunction: Position Statement From the Sexual Medicine Society of North America (SMSNA).

Authors:  James L Liu; Kevin Y Chu; Andrew T Gabrielson; Run Wang; Landon Trost; Gregory Broderick; Kelvin Davies; Gerald Brock; John Mulhall; Ranjith Ramasamy; Trinity J Bivalacqua
Journal:  Sex Med       Date:  2021-05-14       Impact factor: 2.491

8.  Evaluation of a multi-herb supplement for erectile dysfunction: a randomized double-blind, placebo-controlled study.

Authors:  Gaurang R Shah; Manojkumar V Chaudhari; Suresh B Patankar; Shrikant V Pensalwar; Vilas P Sabale; Navneet A Sonawane
Journal:  BMC Complement Altern Med       Date:  2012-09-15       Impact factor: 3.659

Review 9.  A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy.

Authors:  Samuel L Washington; Alan W Shindel
Journal:  Drug Des Devel Ther       Date:  2010-09-07       Impact factor: 4.162

Review 10.  Toward a new 'EPOCH': optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction.

Authors:  R Sadovsky; G B Brock; S W Gutkin; S Sorsaburu
Journal:  Int J Clin Pract       Date:  2009-08       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.